{"id":"pf-06863135-dexamethasone","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"CYP3A4 inhibitors","action":"Avoid","effect":"Increased risk of adverse effects"},{"drug":"CYP3A4 inducers","action":"Avoid","effect":"Decreased efficacy"},{"drug":"CYP2C8 inhibitors","action":"Avoid","effect":"Increased risk of adverse effects"},{"drug":"CYP2C8 inducers","action":"Avoid","effect":"Decreased efficacy"},{"drug":"CYP2C19 inhibitors","action":"Avoid","effect":"Increased risk of adverse effects"},{"drug":"CYP2C19 inducers","action":"Avoid","effect":"Decreased efficacy"},{"drug":"CYP2D6 inhibitors","action":"Avoid","effect":"Increased risk of adverse effects"},{"drug":"CYP2D6 inducers","action":"Avoid","effect":"Decreased efficacy"},{"drug":"CYP1A2 inhibitors","action":"Avoid","effect":"Increased risk of adverse effects"},{"drug":"CYP1A2 inducers","action":"Avoid","effect":"Decreased efficacy"},{"drug":"dexamethasone","action":"Monitor","effect":"Increased risk of adverse effects"}],"commonSideEffects":[],"contraindications":["Hypersensitivity to PF-06863135, dexamethasone, or any of the excipients","Severe hepatic impairment","Concomitant use with strong CYP3A4 inhibitors or inducers"],"specialPopulations":{"Pregnancy":"Not pregnant and willing to use contraception","Geriatric use":"Ages > 18","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-06863135-dexamethasone","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:47:52.026588+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:47:58.411792+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:47:52.054617+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06863135-dexamethasone","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:47:59.188076+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1697787/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:48:00.070339+00:00"}},"allNames":"pf-06863135 + dexamethasone","offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"PF-06863135 + dexamethasone (pf-06863135-dexamethasone) is a marketed drug by Pfizer Inc. for Multiple Myeloma. It has generated $21.2B in revenue. The mechanism of action is not specified. This drug has 7 trials and 0 publications. It is a significant commercial entity. There are no pipeline developments mentioned.","brandName":"PF-06863135 + dexamethasone","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Unknown","novelty":"Best-in-class","modality":"Small molecule","drugClass":"Unknown","explanation":"","oneSentence":"","technicalDetail":"The mechanism of action of PF-06863135 + dexamethasone is not specified, but it is known to be used in the treatment of Multiple Myeloma. The drug has generated significant revenue and has 7 trials. Further research is required to determine the exact mechanism of action."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:38.645Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"$21.2B","peakSalesEstimate":"$21.2B"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-06863135-dexamethasone","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06863135-dexamethasone","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:48:01.998868+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Pomalidomide + dexamethasone","company":"Celgene","advantage":"Pomalidomide + dexamethasone is an immunomodulatory therapy that targets multiple myeloma cells, offering an alternative to PF-06863135 + dexamethasone.","genericName":"Pomalidomide and dexamethasone"},{"name":"Daratumumab + bortezomib + dexamethasone","company":"Janssen Pharmaceuticals","advantage":"Daratumumab + bortezomib + dexamethasone is a combination therapy that targets multiple myeloma cells through different mechanisms, providing an alternative to PF-06863135 + dexamethasone.","genericName":"Daratumumab, bortezomib, and dexamethasone"},{"name":"Carfilzomib + dexamethasone","company":"Amgen","advantage":"Carfilzomib + dexamethasone is a proteasome inhibitor therapy that targets multiple myeloma cells, offering an alternative to PF-06863135 + dexamethasone.","genericName":"Carfilzomib and dexamethasone"}],"genericName":"pf-06863135-dexamethasone","indications":{"approved":[{"name":"Multiple Myeloma","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05020236","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-10-04","conditions":"Multiple Myeloma","enrollment":944},{"nctId":"NCT05675449","phase":"PHASE1","title":"A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-12-14","conditions":"Multiple Myeloma","enrollment":59},{"nctId":"NCT06152575","phase":"PHASE3","title":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-02-08","conditions":"Multiple Myeloma","enrollment":492},{"nctId":"NCT05623020","phase":"PHASE3","title":"A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-11-10","conditions":"Multiple Myeloma","enrollment":1116},{"nctId":"NCT05090566","phase":"PHASE2","title":"MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-10-27","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT07247097","phase":"PHASE2","title":"ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-04-15","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible","enrollment":160},{"nctId":"NCT03269136","phase":"PHASE1","title":"PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-11-29","conditions":"Multiple Myeloma","enrollment":101}],"_emaApprovals":[{"date":"","name":"PF-06863135 + dexamethasone","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL1697787","moleculeType":"Small molecule","molecularWeight":"528.57"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL1697787"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:48:01.998868+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}